Neonates with reduced neonatal lung function have systemic low-grade inflammation by Chawes, Bo L.K. et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 21, 2017
Neonates with reduced neonatal lung function have systemic low-grade inflammation
Chawes, Bo L.K.; Stokholm, Jakob; Bønnelykke, Klaus; Pedersen, Susanne Brix; Bisgaard, Hans Flinker
Published in:
Journal of Allergy and Clinical Immunology
Link to article, DOI:
10.1016/j.jaci.2014.11.020
Publication date:
2015
Document Version
Peer reviewed version
Link back to DTU Orbit
Citation (APA):
Chawes, B. L. K., Stokholm, J., Bønnelykke, K., Pedersen, S. B., & Bisgaard, H. F. (2015). Neonates with
reduced neonatal lung function have systemic low-grade inflammation. Journal of Allergy and Clinical
Immunology, 135(6), 1450-1456. DOI: 10.1016/j.jaci.2014.11.020
  Chawes BL et al. 
Reduced Neonatal Lung Function Associates with Systemic Low-grade 1 
Inflammation in Early Life  2 
Authors: Bo L K Chawes, MD, PhD1; Jakob Stokholm MD, PhD1+3; Klaus Bønnelykke, MD, 3 
PhD1; Susanne Brix, MSc, PhD2; Hans Bisgaard, MD, DMSc1 4 
(1) Copenhagen Prospective Studies on Asthma in Childhood 5 
Health Sciences, University of Copenhagen & 6 
Danish Pediatric Asthma Center  7 
Copenhagen University Hospital, Gentofte; Denmark 8 
(2) Center for Biological Sequence Analysis,  9 
Department of Systems Biology 10 
Technical University of Denmark; Lyngby; Denmark 11 
(3) Department of Pediatrics, Naestved Hospital, Naestved; Denmark. 12 
Corresponding author:  13 
Professor Hans Bisgaard 14 
Copenhagen Prospective Studies on Asthma in Childhood 15 
Health Sciences, University of Copenhagen & 16 
Danish Pediatric Asthma Center  17 
Copenhagen University Hospital, Gentofte 18 
Ledreborg Allé 34 19 
2820 Gentofte 20 
  Chawes BL et al. 
Denmark 21 
Tel: +45 39777360 22 
Fax: +45 39777129 23 
E-mail: bisgaard@copsac.com 24 
Website: www.copsac.com 25 
Article Type: Original article 26 
Word Count: 3,172 words  27 
Tables: 3 28 
Figures: 3 29 
Running Head:  Infant Lung Function and Systemic Low-grade Inflammation 30 
Descriptor Number: XXX  31 
Contributions: The guarantor of the study is HB who has been responsible for the integrity of the 32 
work as a whole, from conception and design to conduct of the study and acquisition of data, 33 
analysis and interpretation of data and writing of the manuscript. BC, SB, JS and KB were 34 
responsible for data analysis, interpretation and writing the manuscript. SB was responsible for the 35 
laboratory mediator assessments. All co-authors have contributed substantially to the analyses and 36 
interpretation of the data, and have provided important intellectual input and approval of the final 37 
version of the manuscript. 38 
Source of Funding: COPSAC is funded by private and public research funds listed on 39 
www.copsac.com. The Lundbeck Foundation; The Danish Strategic Research Council; the 40 
  Chawes BL et al. 
Pharmacy Foundation of 1991; Augustinus Foundation; the Danish Medical Research Council and 41 
The Danish Pediatric Asthma Centre provided the core support for COPSAC research center. No 42 
pharmaceutical company was involved in the study. The funding agencies did not have any role in 43 
design and conduct of the study; collection, management, and interpretation of the data; or 44 
preparation, review, or approval of the manuscript. 45 
Abbreviations: COPSAC2000 = COpenhagen Prospective Study on Asthma in Childhood; CXCL8 46 
(IL-8) = Chemokine (C-X-C motif) Ligand 8; FEV0.5 = Forced Expiratory Volume at 0.5 seconds; 47 
FEF50 = Forced Expiratory Flow at 50% of the forced vital capacity; hs-CRP = high-sensitivity C-48 
reactive protein; IL-1β = Interleukin-1β, IL-6 = Interleukin-6; MMEF = Maximal Mid-Expiratory 49 
Flow; PtcO2 = transcutaneuos oxygen saturation; PD15 = Provocative Dose of methacholine causing 50 
a 15% drop in PtcO2; PD20 = Provocative Dose of methacholine causing a 20% drop in FEV1 from 51 
baseline; TNF-α = tumor necrosis factor-α; TROLS = TROublsome Lung Symptoms. 52 
Online Repository: This article has an online data supplement, which is accessible from this issue's 53 
table of content online at www.atsjournals.org. 54 
At a Glance Commentary: 55 
Scientific Knowledge on the Subject 56 
Elevated hs-CRP as a proxy of systemic low-grade inflammation has been demonstrated in 57 
asthmatic children and adults with diminished pulmonary function. It is however unknown whether 58 
asymptomatic reduced neonatal lung function is associated with systemic inflammation. 59 
What this Study Adds to the Field 60 
This study shows that children with impaired respiratory capacity as neonates are characterized by 61 
elevated hs-CRP and an up-regulated blood inflammatory profile suggesting presence of systemic 62 
low-grade inflammation in early life.   63 
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Data from this manuscript has not been presented before in abstract or any other form.  64 
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ABSTRACT 65 
Rationale 66 
Previous studies indicate presence of systemic inflammation in children and adults with asthma and 67 
impaired lung function, but it is unknown whether asymptomatic reduced infant lung function is 68 
associated with low-grade inflammation in early life.  69 
Objective 70 
To investigate the possible association between infant lung function indices and biomarkers of 71 
systemic inflammation in early life. 72 
Methods 73 
Serum levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-1β (IL-1β), IL-6, tumor 74 
necrosis factor-α (TNF-α) and CXCL8 (IL-8) were measured at age 6 months in 300 children of the 75 
Copenhagen Prospective Study on Asthma in Childhood2000 (COPSAC2000) birth cohort, who 76 
completed infant lung function testing at age 1 month, spirometry at 7yrs, and fulfilled a respiratory 77 
day-to-day diary from 0-7yrs. Associations between lung function indices, asthmatic symptoms and 78 
inflammatory biomarkers were investigated by conventional statistics and unsupervised principle 79 
component analysis.  80 
Measurements and Main Results 81 
Infant’s forced expiratory volume at 0.5s (FEV0.5) was inversely associated with hs-CRP (β-82 
coefficient, -0.12; 95% CI, -0.21 to -0.04; p=0.004) and with a uniform up-regulated inflammatory 83 
signature (p=0.02). hs-CRP at 6mo was elevated in children with asthmatic symptoms at 0-6mo 84 
compared to children without asthmatic symptoms (median, 1.79mg/L vs. 1.19mg/L; p=0.05), but 85 
was not associated with asthma or lung function at age 7yrs. Adjusting for older children in the 86 
home, infections 14d prior to blood sampling, birth BMI, and maternal smoking did not affect the 87 
associations.  88 
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Conclusion 89 
Diminished infant lung function associates with elevated hs-CRP and an up-regulated blood 90 
inflammatory response suggesting linkage between lung function and systemic low-grade 91 
inflammation in early life. 92 
Abstract Word Count: 252 words 93 
Key-words: Asthma, Children, high-sensitivity C-reactive protein, pro-inflammatory cytokines, 94 
spirometry.  95 
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INTRODUCTION 96 
C-reactive protein (CRP) is an acute-phase reactant found in the blood in response to acute and 97 
chronic inflammatory conditions and has a broad clinical application in the screening for infectious 98 
and immune-mediated diseases1. CRP harbors important innate immunity properties and is released 99 
from the liver triggered by pro-inflammatory cytokines such as interleukin 6 (IL-6), IL-1β, and 100 
tumor necrosis factor α (TNF-α)2. Newer CRP assays3 has enabled assessment of previously 101 
immeasurable low levels of CRP, termed high sensitivity CRP (hs-CRP), which is now increasingly 102 
recognized as a marker of low-grade inflammation in e.g. cardiovascular disease4, obesity5, and 103 
diabetes mellitus6. 104 
Recently, elevated hs-CRP has also been demonstrated in manifest airway diseases such as asthma7 105 
and chronic obstructive pulmonary disease8. In addition, previous studies indicate that impaired 106 
lung function in asthmatic children and adults is associated with presence of systemic low-grade 107 
inflammation9,10. It is however unknown whether asymptomatic neonates with reduced pulmonary 108 
function are characterized by systemic low-grade inflammation in early life. 109 
We hypothesized that children with reduced neonatal lung function may have biochemical signs of 110 
systemic low-grade inflammation in infancy. The objective of the current study was therefore to 111 
investigate the possible association between lung function indices measured in asymptomatic 112 
neonates of the Copenhagen Prospective Study on Asthma in Childhood2000 (COPSAC2000) birth 113 
cohort and serum levels of hs-CRP, IL-1β, IL-6, TNF-α, and CXCL8 (formerly IL-8) at age 6 114 
months.  115 
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METHODS 116 
Study Cohort 117 
The study participants were 411 infants born of mothers with a history of asthma enrolled at 1 118 
month of age in the COPSAC2000 prospective birth cohort study11-13. Exclusion criteria were any 119 
respiratory symptoms or respiratory support prior to inclusion, gestational age <36 weeks, and any 120 
congenital abnormality or systemic illness. The children attended the COPSAC research clinic at 121 
age 1 month for assessment of infant lung function and subsequently at 6-monthly intervals till age 122 
7 years for scheduled clinical investigations, collection of medical history since last visit supported 123 
by a day-to-day lung symptom diary, and for detailed exposure assessments. Additional acute visits 124 
were arranged upon occurrence of any respiratory symptoms.   125 
Ethics 126 
The study was conducted in accordance with the guiding principles of the Declaration of Helsinki 127 
and was approved by the Local Ethics Committee (KF 01-289/96), and the Danish Data Protection 128 
Agency (2008-41-1754). Both parents gave written informed consent before enrolment. 129 
Inflammatory Biomarkers 130 
At age 6 months blood was drawn from a cubital vein, centrifuged to separate serum and serum 131 
cells, and immediately stored at -80° C until analyses. The samples were transported on dry ice to 132 
the laboratory, where levels of the selected biomarkers were determined by high-sensitivity ELISA 133 
assays based on electrochemiluminescence in a 4-plex setting for IL-1β, IL-6, CXCL8 and TNF-α 134 
and as a single assay for hs-CRP. Samples were read in duplicates using the Sector Imager 6000 135 
(MesoScale Discovery®, Gaithersburg, MD, USA). The limit of detection (mean signal from blanks 136 
+3SD) was 9.54 pg/mL for hs-CRP, 0.15 pg/mL for IL-1β, 0.17 pg/mL for IL-6, 0.09 pg/mL for 137 
CXCL8 and 0.08 pg/mL for TNF-α.  138 
Lung Function 139 
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Infant spirometry was measured at age 1 month applying the raised volume rapid thoraco-140 
abdominal “squeeze”-jacket compression technique14. Repeated ventilations to predefined mouth-141 
pressures assured expansion of the lung volume before an instant inflation of the jacket caused a full 142 
exhalation during which the flow was measured by a pneumotachograph with an aircushion 143 
facemask15,16. The software identified the Forced Vital Capacity (FVC) as the first plateau on the 144 
volume-time curve and measurements with FVC appearing after 0.5s and with the Forced 145 
Expiratory Volume at 0.5s (FEV0.5) being smaller than or equal to FVC were accepted. Three to 146 
five acceptable curves were obtained for each infant and the curve containing the median value of 147 
FEV0.5 was used for the analyses of FEV0.5 and Forced Expiratory Flow at 50% of FVC (FEF50). 148 
Spirometry at age 7yrs was performed as previously detailed17 using a pneumotachograph, 149 
Masterscope Pneumoscreen, system 754,916 spirometer (Erich Jaeger, Wurtzburg, Germany) for 150 
assessing FEV1 and maximal mid-expiratory flow (MMEF). 151 
Infant bronchial responsiveness: After an initial saline inhalation, methacholine was given in 152 
quadrupling dose-steps via a dosimeter attached to a nebulizer (SPIRA 08 TSM 133; Respiratory 153 
Care Center; Hämeenlinna, Finland)16. Bronchial responsiveness was determined by continuous 154 
assessment of transcutaneuos oxygen saturation (PtcO2) (TCM3; Radiometer; Copenhagen, 155 
Denmark). The provocative dose causing a 15% drop in PtcO2 (PD15) was estimated from the dose 156 
response curves fitted with a logistic function. 157 
Bronchial responsiveness at age 7yrs was defined as the provocative dose of methacholine causing a 158 
20% drop in FEV1 from baseline (PD20)17.  159 
Clinical Investigator-diagnosed End-points 160 
Troublesome lung symptoms (TROLS) were defined as significant cough or wheeze or dyspnea 161 
severely affecting the well-being of the child and recorded by the parents in a daily diary chart as a 162 
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dichotomized score (yes/no) from birth till age 7yrs18. Recurrent TROLS was defined from the 163 
diaries as five episodes within 6 months, each episode lasting at least three consecutive days, or 164 
daily symptoms for four consecutive weeks19,20.  165 
Asthma at age 7yrs was diagnosed according to international guidelines and was based on recurrent 166 
TROLS as defined above, symptoms judged by the COPSAC pediatricians to be typical of asthma, 167 
in need of intermittent inhaled β2-agonist, responding to a 3-month trial of inhaled corticosteroids 168 
and relapsing when stopping treatment12,13. 169 
Covariates 170 
Covariates included heredity (father’s history of asthma, eczema or allergy [yes/no]); 171 
anthropometrics (birth BMI [7-12, 12-13, 13-14, 14-17m/kg2]); demographics (gender, older 172 
children in the home at birth [yes/no], yearly household income [low (<53.000 €), medium (53.000-173 
80.000 €), high (>80.000 €)]); pre- and antenatal exposures (maternal smoking during 3rd 174 
pregnancy trimester [yes/no], caesarean section [yes/no]); postnatal exposures (solely breastfeeding 175 
length [0-3, 3-6, >6mo], age at start in daycare [0-9, 9-12, >12mo], pets in the home in the 1st year 176 
of life: cat [yes/no], dog [yes/no]); and infections 14 days prior to biomarker assessment (upper and 177 
lower respiratory tract infections, gastroenteritis or fever with unknown cause [yes/no]).   178 
Statistics 179 
Biomarker null values were set to half of the lowest detected value for the specific biomarker, 180 
values were log-transformed, and the mean of the duplicate measurements were used for association 181 
analyses. Z-scores were calculated for FEV0.5, FEV1, FEF50 and MMEF, and PD15 and PD20 were 182 
log-transformed to obtain normality. The associations between lung function, asthmatic symptoms, 183 
and inflammatory biomarkers were tested by conventional statistics and by unsupervised pattern 184 
recognition using principal component analysis (PCA).  185 
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The relation between continuous lung function indices and continuous levels of inflammatory 186 
biomarkers at age 6 months was tested with general linear models. The association between 187 
biomarker levels and time to recurrent TROLS was modeled using Cox-regression. Logistic 188 
regression was used to compute the odds ratio of asthma at age 7yrs. 189 
For the pattern recognition analyses, we extracted underlying orthogonal components that described 190 
the systematic part of the variation across the biomarkers using centered and scaled (equal variance) 191 
mediator levels. Scree plots of the Eigen values were used to select the number of components for 192 
subsequent association analyses.  193 
All results are presented as raw estimates with 95% CI and as estimates adjusted for covariates 194 
associated with levels of hs-CRP using a cut-off at p≤0.10. Birth BMI and maternal smoking during 195 
3rd trimester were retained in the multivariable models with infant lung function independently of 196 
their association with hs-CRP as these are important determinants of infant lung function21. A p-197 
value≤0.05 was considered significant. All analyses were done using SAS version 9.3 (SAS 198 
Institute, Cary, NC).  199 
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RESULTS 200 
Inflammatory Biomarker Assessments 201 
Measurements of IL-1β, IL-6, TNF-α and CXCL8 were performed on 309 and hs-CRP on 301 202 
serum samples collected at age 6 months. One sample was lost for technical reasons while 203 
performing the 4-plex assay, resulting in 300 children (73% of the original 411 cohort children) 204 
with available measurements for all five biomarkers. We found no significant differences in 205 
baseline characteristics between children with and without available biomarker assessments (Table 206 
E1). 207 
The median hs-CRP level was 1.39 mg/L (inter-quartile range [IQR], 0.46-4.61), IL-1β was 0.01 208 
ng/L (0.001-0.04), IL-6 was 0.20 ng/L (0.11-0.31), TNF-α was 2.34 ng/L (1.92-2.88), and CXCL8 209 
was 3.04 ng/L (2.19-4.37). The IL-6 and TNF-α levels were strongly positively correlated with hs-210 
CRP levels (p<0.001 for both) whereas IL-1β and CXCL8 levels were not correlated with hs-CRP 211 
(p≥0.62). The measured values of hs-CRP, IL-6, TNF-α and CXCL8 were within the expected 212 
range22 with very few null values, whilst IL-1β levels were much lower than expected22 with null 213 
values for 72 of 308 children (23%). Due to that and the fact that IL-1β has been shown to 214 
significantly degrade over time even at -80° C23, IL-1β was not included in further analyses. 215 
Determinants of hs-CRP 216 
Children with older children in the home at birth had significantly higher hs-CRP level at age 6 217 
months compared to children without older children in the home: median hs-CRP level 2.20 mg/L 218 
(IQR, 0.63-5.05) vs. 1.16 mg/L (0.41-3.40), p=0.005. In addition, hs-CRP was elevated in children 219 
who had suffered an infectious episode within 14 days prior to biomarker assessment compared to 220 
children without apparent infections: 4.29 mg/L (1.71-5.34) vs. 0.84 mg/L (0.36-2.67), p<0.0001. 221 
We did not detect associations between hs-CRP level and paternal history of asthma, eczema or 222 
allergy, child gender, birth BMI, household income, maternal smoking during 3rd pregnancy 223 
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trimester, birth by caesarean section, breastfeeding, daycare attendance or pets in the home (Table 224 
1).   225 
Lung Function and Systemic Low-grade Inflammation  226 
The conventional statistical approach showed a strong linear inverse association between FEV0.5 at 227 
age 1 month and hs-CRP level at age 6 months (β-coefficient, -0.12; 95% CI, -0.21 to -0.04; 228 
p=0.004) suggesting increasing grade of inflammation by diminished neonatal lung volume (Figure 229 
1). The association was unaffected by adjustment for older children in the home, infections 14 days 230 
prior to biomarker assessment, birth BMI and maternal smoking in 3rd trimester: β-coefficient, -231 
0.13; 95% CI, -0.22 to -0.04; p=0.005. FEF50 also seemed inversely associated with hs-CRP, but 232 
was not significant: β-coefficient, -0.06; 95% CI, -0.15 to 0.02; p=0.14.  233 
Increasing FEV0.5 was also significantly associated with decreasing levels of IL-6 (β-coefficient, -234 
0.10; 95% CI, -0.18 to -0.01; p=0.03) (Figure 2). Confounder adjustment did not modify the 235 
association: β-coefficient, -0.09; 95% CI, -0.18 to 0.00; p=0.04. We did not detect a significant 236 
association between FEF50 and IL-6 levels.  237 
FEV0.5 and FEF50 measurements were not associated with CXCL8 or TNF-α levels although the β-238 
coefficients suggested an inverse association between lung function indices and TNF-α (Table 2). 239 
The unsupervised PCA showed that hs-CRP, IL-6, TNF-α and CXCL8 were positively correlated in 240 
the first principal component (PC1) which explained 41% of the total variation in the data. The PCA 241 
approach is illustrated in the biplot (Figure 3) showing scores for PC1 and PC2 and loadings for the 242 
biomarkers. Because of the univocal pattern in PC1, we focused on PC1 in the further analyses. 243 
Confirming the findings from the conventional statistics, we found that FEV0.5 was inversely 244 
associated with PC1 (p=0.02) and remained significant after confounder adjustments (p=0.03). The 245 
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β-coefficients also suggested an inverse association between FEF50 and PC1, but the model was not 246 
significant (Table 2).  247 
We did not detect any association between inflammatory biomarkers at age 6 months and lung 248 
function at age 7 years neither by conventional statistics nor by PCA approach (Table E2).    249 
Bronchial Responsiveness and Systemic Low-grade Inflammation 250 
Bronchial responsiveness to methacholine in neonatal life and at age 7 years was not associated 251 
with biomarkers of low-grade inflammation at age 6 months (Tables 2 and E2). 252 
Lung Symptoms, Asthma and Systemic Low-grade Inflammation 253 
Children experiencing TROLS at any time-point from birth till biomarker assessment (0-6mo) 254 
compared to children without TROLS had significantly elevated levels of hs-CRP: median 1.79 255 
mg/L (IQR,0.50-4.72) vs. 1.19 mg/L (0.46-4.14), p=0.05; IL-6: 0.21 ng/L (0.13-0-42) vs. 0.19 ng/L 256 
(0.11-0.29), p=0.05; and CXCL8: 3.37 ng/L (2.18-5.31) vs. 2.90 ng/L (2.22-3.85), p=0.04. The 257 
PCA approach confirmed an up-regulated blood inflammatory profile in children experiencing 258 
TROLS at age 0-6mo (p=0.01). The findings were unaffected by adjustment for older children in 259 
the home and infectious episodes within 14 days prior to biomarker assessment (Table 3).  260 
Elevated hs-CRP showed a trend of a 1.5-fold increased risk of recurrent TROLS till age 1yr 261 
(hazard ratio, 1.5; 95% CI, 0.9-2.5, p=0.10), but was not associated with recurrent TROLS after age 262 
1yr or asthma at age 7yrs. Similar associations were detected with IL-6 and PC1 (Table 3).    263 
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 DISCUSSION 264 
Key Findings 265 
This study shows that children with reduced pulmonary capacity as neonates are characterized by 266 
elevated levels of hs-CRP and a generally up-regulated blood inflammatory response suggesting 267 
presence of systemic low-grade inflammation in early childhood. These findings indicate that 268 
reduced infant lung function reflects an ongoing asymptomatic airway inflammation with a 269 
measurable systemic component early in life.      270 
Strengths and Limitations of the Study   271 
A major strength of the study is the unique assessment of neonatal lung function with the state-of-272 
the-art raised volume rapid thoraco-abdominal compression technique performed strictly in 273 
coherence with recognized guidelines14. The infant spirometry measurements were obtained in a 274 
large sample of asymptomatic children prior to presence of any respiratory symptoms and are thus 275 
unbiased from preexisting or concurrent airway disease. Another significant strength of the study is 276 
the availability of a range of environmental exposure assessments enabling robust confounder 277 
adjustment for factors with possible influence on infant lung function and low-grade inflammation. 278 
There were strong linear correlations between IL-6 and TNF-α and hs-CRP levels. As IL-6 and 279 
TNF-α are main triggers of CRP release from the liver2, these expected correlations serve as a 280 
biological validation of the data. The lack of correlation between CXCL8 and hs-CRP levels was 281 
not surprising because CXCL8 primarily has a neutrophilic chemotactic function in the innate 282 
immune system and does not directly induce CRP release24. The finding of significantly elevated 283 
hs-CRP levels in children experiencing an infectious episode within 14 days prior to biomarker 284 
assessment further assures a high signal-to-noise ratio as CRP is a reliable biomarker of ongoing 285 
infection1. Even after adjusting for this potentially strong confounder, the association between 286 
infant lung function and hs-CRP persisted with largely unchanged effect estimates. Furthermore, 287 
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both the standard statistical approach and the unsupervised data driven approach revealed identical 288 
associations enhancing our confidence in the findings of the study. 289 
It is a limitation of the study that we were unable to detect a biologically meaningful signal from IL-290 
1β which is presumably partly due to the sample storage time of up to 13 years. It is well known 291 
that circulating IL-1β levels are approximately x5 lower than TNF-α in healthy adults22, but in our 292 
case the median IL-1β level was x200 lower than the median TNF-α level (0.01 vs. 2.34ng/L) and 293 
we were unable to detect association between IL-1β and hs-CRP. This was not unexpected as IL-1β 294 
is particularly sensitive to freeze-thaw cycles and degrades >50% over time, even when samples are 295 
stored at -80 degree C23. 296 
Another limitation of the study is the at-risk nature of the cohort, as all children are born to mothers 297 
with a history of asthma. We recently demonstrated that the offspring of mothers with a history of 298 
asthma, allergy or eczema in an unselected mother-child cohort has a topical down-regulated 299 
immune signature in the airway mucosa compared to children of mothers without such disorders25. 300 
The at-risk nature of the studied cohort may have impacted the measured biomarker levels but 301 
should not hamper our ability to explore the association between infant spirometry incentives and 302 
evident markers of systemic low-grade inflammation within the cohort. 303 
Meaning of the Study 304 
The strong linear inverse association between infant lung function and hs-CRP proposes that 305 
neonates with diminished lung function are characterized by manifest systemic low-grade 306 
inflammation very early in life. This suggests that airway inflammation accompanies reduced lung 307 
function even in asymptomatic neonates and that such airway inflammation is not a local 308 
phenomenon but has a measurable systemic component. To our knowledge, no other previous study 309 
has investigated the relationship between infant lung function and low-grade inflammation in early 310 
life. 311 
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Hitherto, only very few childhood studies have investigated hs-CRP level in relation to pulmonary 312 
function outcomes9,26,27. In line with our findings, a study of 63 asthmatic children aged 2-12 years 313 
with and without acute exacerbations27 and a study of 60 school-aged children treated with inhaled 314 
corticosteroids as well as steroid-naïve children9 showed a reciprocal relationship between FEV1 315 
and hs-CRP. In contrast, another similar study of 62 school-aged children with controlled and 316 
uncontrolled asthma26 did not detect association between hs-CRP and FEV1, but found that hs-CRP 317 
was higher in uncontrolled vs. controlled asthma which may reflect degree of airway inflammation. 318 
All these studies are significantly hampered by low numbers and wide age-ranges and solely 319 
investigate children with manifest asthma. Our study extends the current knowledge by 320 
demonstrating an association between hs-CRP and infant lung function measured at age 1 month in 321 
asymptomatic neonates prior to onset of any respiratory symptoms. 322 
In support of our findings, a number of recent larger cross-sectional analyses in adult and adolescent 323 
studies have shown that increased hs-CRP is associated with respiratory impairment in both 324 
population-based settings and in asthmatic and non-asthmatic strata10,28,29. Longitudinal lung 325 
function follow-up performed 6-9 years after baseline in these studies and in another similar study 326 
showed no association between baseline hs-CRP and follow-up FEV128-30. In line with those 327 
findings, we found no association between hs-CRP in early life and lung function at age 7 years 328 
suggesting that low-grade systemic inflammation mainly reflects current airway inflammation and 329 
does not predict subsequent decline in lung function. This hypothesis aligns with our finding of 330 
elevated hs-CRP being associated with a recent history of asthma-like symptoms and an increased 331 
risk of developing recurrent asthma-like symptoms in the first year of life but not thereafter. 332 
A possible explanation of the identified association between reduced infant lung function and 333 
elevated hs-CRP is that diminished forced volume is accompanied by airway inflammation with a 334 
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systemic component. Thus, in vitro murine and human lung cell studies have established a possible 335 
role of the pro-inflammatory cytokines stimulating CRP release such as IL-6, TNF-α and IL-1β in 336 
the pathophysiology of obstructive airway inflammation31,32. Persistently elevated CRP may induce 337 
an increased vulnerability to changes in the early life environment through its actions as a general 338 
scavenger protein with important innate immune functions in the recognition and elimination of 339 
bacteria and damaged human cells via opsonization, phagocytosis, and cell-mediated cytotoxicity1. 340 
Alternatively, reduced neonatal lung function does not per se trigger systemic inflammation, but is 341 
rather an independent characteristic of infants with a less efficient inflammatory regulation leading 342 
to a cycle of sustained low-grade inflammation in early life. Such inefficient immune-regulation 343 
might be driven by the infant’s genotype interacting with the intra uterine and early-in-life 344 
environment, thereby affecting the plasticity of the developing immune system. In support of the 345 
latter theory, higher baseline CRP levels has been demonstrated in westernized populations where 346 
obstructive airway disorders are more prevalent compared to rural societies33.  347 
Conclusion 348 
Children of the Danish COPSAC2000 at-risk cohort with reduced infant lung function are 349 
characterized by elevated hs-CRP level and an up-regulated blood inflammatory response 350 
suggesting that reduced lung function reflects an ongoing asymptomatic airway inflammation with a 351 
measurable systemic component early in life.  352 
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TABLES 353 
Table 1: Heredity, anthropometrics, demographics, pre-, peri- and postnatal exposures, and 354 
infectious episodes prior to assessment of low-grade inflammation in relation to hs-CRP level at age 355 
6 months. 356 
 hs-CRP (mg/L) at age 6 months 
Characteristic N Median (IQR) P-value 
Paternal asthma, allergy or eczema Yes 135 1.52 (0.46-4.61) 0.54 
No 153 1.31 (0.46-4.44) 
Gender Male 155 1.37 (0.37-4.44) 0.62 
Female 146 1.51 (0.49-4.81) 
Body mass index (BMI) at birth 7-12m/kg2 78 1.06 (0.45-4.46) 0.56 
12-13m/kg2 73 1.80 (0.56-4.69) 
13-14m/kg2 74 1.41 (0.48-4.98) 
14-17m/kg2 76 1.25 (0.39-3.75) 
Older children in the home at birth Yes 114 2.20 (0.63-5.05) 0.005 
No 177 1.16 (0.41-3.40) 
Household income at birth (yearly)* Low 77 0.83 (0.38-3.57) 0.17 
Average 144 1.31 (0.46-4.63) 
High 70 2.27 (0.67-4.92) 
Maternal smoking during 3rd trimester 
 
Yes 51 1.40 (0.41-4.46) 0.33 
No 250 1.22 (0.64-5.02) 
Cesarean section Yes 60 1.81 (0.52-5.13) 0.20 
No 205 1.31 (0.46-3-93) 
Solely breastfeeding period  0-3mo 64 2.16 (0.49-5.35) 0.43 
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3-6mo 160 1.51 (0.46-4.31) 
>6mo 40 1.02 (0.55-3.87) 
Age at start in daycare 0-9mo 89 1.80 (0.50-5.13) 0.26 
9-12mo 77 1.13 (0.36-3.40) 
>12mo 123 1.59 (0.50-4.82) 
Cat in the home in 1st year of life Yes 46 1.74 (0.67-3.87) 0.42 
No 248 1.41 (0.44-4.67) 
Dog in the home in 1st year of life Yes 44 1.15 (0.50-3.65) 0.56 
No 249 1.52 (0.49-4.69) 
Infection 14 d before hs-CRP 
assessment** 
Yes 95 4.29 (1.71-5.34) <0.0001 
No 206 0.84 (0.36-2.67) 
*Yearly household income at birth of infant: low (<53.000 €), medium (53.000-80.000 €), high 357 
(>80.000 €). 358 
**Infections include any upper or lower respiratory tract infection, gastroenteritis or fever with 359 
unknown cause within 14 days before the blood sampling for hs-CRP measurement.  360 
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Table 2: Association between infant lung function and inflammatory biomarkers at age 6 months: conventional and principal component 361 
analysis approach. 362 
 Log-hs-CRP  Log-IL-6  Log-TNF-α  Log-CXCL8  PC1 
 β-coefficient 
(95% CI) 
p β-coefficient 
(95% CI) 
p β-coefficient 
(95% CI) 
p β-coefficient 
(95% CI) 
p β-coefficient 
(95% CI) 
p 
 UNADJUSTED ANALYSIS 
z-FEV0.5 -0.12 
(-0.21 to -
0.04)  
0.004 -0.10  
(-0.18 to -
0.01) 
0.0
3 
-0.11 
(-0.38 to 
0.17) 
0.44 0.02 
(-0.15 to 
0.19) 
0.83 -0.10 
(-0.19 to -
0.01) 
0.02 
z-FEF50 -0.06 
(-0.15 to 
0.02) 
0.14 -0.02 
(-0.11 to 0.06) 
0.6
1 
-0.09 
(-0.37 to 
0.18) 
0.52 -0.06 
(-0.22 to 
0.11) 
0.49 -0.06 
(-0.14 to 0.03) 
0.17 
Log-PD15 0.04 
(-0.12 to 
0.21) 
0.60 -0.03 
(-0.21 to 0.15) 
0.7
5 
-0.02 
(-0.56 to 
0.52) 
0.94 0.15 
(-0.17 to 
0.46) 
0.36 0.03 
(-0.14 to 0.19) 
0.76 
 ADJUSTED ANALYSIS* 
z-FEV0.5 -0.13 
(-0.22 to -
0.04) 
0.005 -0.09 
(-0.18 to 0.00) 
0.0
4 
-0.13 
(-0.43 to 
0.18) 
0.41 0.02 
(-0.15 to 
0.20) 
0.79 -0.10 
(-0.20 to -
0.01) 
0.03 
z-FEF50 -0.06 
(-0.16 to 
0.03) 
0.18 -0.03 
(-0.12 to 0.06) 
0.4
9 
-0.11 
(-0.42 to 
0.19) 
0.46 -0.06 
(-0.23 to 
0.12) 
0.50 -0.06 
(-0.15 to 0.03) 
0.19 
Log-PD15 0.02 
(-0.16 to 
0.20) 
0.83 -0.03 
(-0.22 to 0.15) 
0.7
2 
-0.06 
(-0.61 to 
0.50) 
0.84 0.15 
(-0.18 to 
0.48) 
0.35 -0.02 
(-0.19 to 0.16) 
0.85 
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PC1 = Principal Component 1; FEV0.5 = Forced Expiratory Volume at 0.5 seconds; FEF50 = Forced Expiratory Flow at 50% of the forced 363 
vital capacity; PD15 = Provocative Dose of methacholine causing a 15% drop in transcutaneuos oxygen saturation. 364 
*Adjusted for birth BMI, maternal smoking during 3rd pregnancy trimester, older children in the home at birth and infectious episodes 365 
within 14days prior to blood sampling for inflammatory biomarkers assessment. 366 
Table 3: Association between inflammatory biomarkers at age 6 months and asthma-related outcomes at 0-7 years: conventional and 367 
principal component analysis approach. 368 
 Log-hs-CRP  Log-IL-6  Log-TNF-α  Log-CXCL8  PC1 
 Estimate 
 (95% CI) 
p Estimate 
 (95% CI) 
p Estimate 
 (95% CI) 
p Estimate 
 (95% CI) 
p Estimate 
 (95% CI) 
p 
 UNADJUSTED ANALYSIS 
Any TROLS, 0-6mo1 0.04 
(0.00-
0.08) 
0.05 0.04 
(0.00-0.09) 
0.05 0.09 
(-0.05-0.23) 
0.18 0.09 
(0.00-0.17) 
0.0
4 
0.06 
(0.01-
0.10) 
0.01 
Recurrent TROLS, 0-
1yr2 
1.5  
(0.9-2.5)  
0.10  1.5 
 (0.9-2.4)  
0.11  1.5 
 (0.4-6.6)  
0.56  1.2  
(0.6-2.3)  
0.6
3  
1.4  
(0.9-2.0)  
0.12  
Recurrent TROLS, 0-
yrs2 
1.0  
(0.8-1.2)  
0.95  1.0 
 (0.8-1.2)  
0.79  1.0 
 (0.6-1.9)  
0.88  0.9  
(0.6-1.3)  
0.4
3  
1.0  
(0.8-1.2)  
0.97  
Asthma, 7yrs3 1.0  
(0.8-1.3)  
0.99  1.0  
(0.7-1.2)  
0.73  0.7  
(0.3-1.6)  
0.36  0.6 
 (0.3-1.3)  
0.1
7  
0.9  
(0.7-1.2)  
0.62  
 ADJUSTED ANALYSIS* 
  Chawes BL et al. 
Any TROLS, 0-6mo1 0.05  
(0.00-
0.09) 
0.04 0.04 
(-0.01-0.08)  
0.08 0.06 
(-0.08-0.21) 
0.40 0.07 
(-0.01-
0.15) 
0.1
1 
0.05  
(0.01-
0.10) 
0.03 
Recurrent TROLS, 0-
1yr2 
1.6 
(0.9-2.7) 
0.09 1.4 
(0.8-2.3) 
0.20 1.3 
(0.3-5.4) 
0.76 1.1 
(0.6-2.0) 
0.7
9 
1.3 
(0.9-1.9) 
0.21 
Recurrent TROLS, 0-
yrs2 
1.0 
(0.8-1.2) 
0.97 1.0 
(0.8-1.1) 
0.62 0.9 
(0.5-1.6) 
0.66 0.8 
(0.5-1.2) 
0.3
0 
1.0 
(0.8-1.2) 
0.68 
Asthma, 7yrs3 1.0 
(0.8-1.3) 
0.97 0.9 
(0.7-1.2) 
0.66 0.6 
(0.3-1.4) 
0.26 0.6 
(0.3-1.2) 
0.1
5 
0.9 
(0.7-1.2) 
0.43 
PC1 = Principal Component 1; TROLS = TROublesome Lung Symptoms. 369 
*Adjusted for older children in the home at birth and infectious episodes within 14days prior to blood sampling for inflammatory 370 
biomarkers assessment. 371 
1Occurence of any TROLS from birth till age 6 months: general linear model (estimate=β-coefficent). 372 
2Time to onset of recurrent TROLS: Cox regression (estimate=hazard ratio). 373 
3Asthma at age 7 years (yes/no): logistic regression (estimate=odds ratio).  374 
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Table E1 Online: Comparison of baseline characteristics between children with and without 375 
complete assessment of early-life low-grade inflammation. 376 
Baseline characteristic Children with 
biomarker 
assessment 
N=300 
Children without 
biomarker 
assessment 
N=111 
p 
Paternal asthma, allergy or eczema, % 
(N) 
47% (135) 46% (50) 0.84c 
Male gender, % (N) 51% (154) 44% (49) 0.20c 
BMI at birth, mean (SD) 12.79m/kg2 (1.34) 12.84m/kg2 (1.22) 0.63t 
Older children in the home at birth, % 
(N) 
39% (114) 40% (38) 0.91c 
Household income at birth*, % (N)   0.12c 
   Low 27% (77) 38% (35)  
   Average 49% (143) 41% (39)  
   High 24% (70) 21% (20)  
Maternal smoking during 3rd trimester, 
% (N) 
17% (51) 11% (12) 0.12c 
Cesarean section, % (N) 23% (60) 27% (25) 0.45c 
Solely breastfeeding length, median 
(IQR) 
122days (90-155) 122days (74-164) 0.90w 
Age at start in daycare, median (IQR) 345days (240-415) 307days (216-412)  0.27w 
Cat in the home in 1st year of life, % 
(N) 
16% (46) 14% (14) 0.61c 
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Dog in the home in 1st year of life, % 
(N) 
15% (44) 10% (10) 0.16c 
*Yearly household income at birth of infant: low (<53.000 €), medium (53.000-80.000 €), high 377 
(>80.000 €), cChi-square test, tt-test, wWilcoxon rank sum test 378 
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Table E2: Association between inflammatory biomarkers at age 6 months and lung function at age 7 years: conventional and principal 379 
component analysis approach. 380 
 Log-hs-CRP  Log-IL-6  Log-TNF-α  Log-CXCL8  PC1 
 β-coefficient 
(95% CI) 
p β-coefficient 
(95% CI) 
p β-coefficient 
(95% CI) 
p β-coefficient 
(95% CI) 
p β-coefficient 
(95% CI) 
p 
z-FEV1 0.04 
(-0.06-0.15)  
0.45  0.02  
(-0.08-0.12)  
0.68  0.20  
(-0.12-0.52)  
0.21  0.18 
 (-0.03-0.40)  
0.09  0.05 
 (-0.05-0.15)  
0.32  
z-MMEF 0.01  
(-0.10-0.11)  
0.92  -0.01  
(-0.11-0.10)  
0.91  0.11  
(-0.23-0.44)  
0.53  0.14  
(-0.09-0.36)  
0.23  0.03  
(-0.08-0.14)  
0.57  
Log-PD20 0.13  
(-0.15-0.29)  
0.08  0.09 
(-0.06-0.25)  
0.24  0.30 
(-0.15-0.75)  
0.19  0.02 
(-0.30-0.34)  
0.90  0.07 
(-0.07-0.21)  
0.34  
PC1 = Principal Component 1; FEV1 = Forced Expiratory Volume at 0.5 seconds; MMEF = Maximal Mid-Expiratory Flow; PD20 = 381 
Provocative Dose of methacholine causing a 20% drop in FEV1 from baseline.  382 
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FIGURES 383 
Figure 1: Scatter plot illustrating the relationship between neonatal lung function (z-score of 384 
FEV0.5) and hs-CRP at age 6 months (log-transformed values). 385 
 386 
  387 
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Figure 2: Scatter plot illustrating the relationship between neonatal lung function (z-score of 388 
FEV0.5) and IL-6 at age 6 months (log-transformed values). 389 
 390 
  391 
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Figure 3: Principal component analysis biplot showing scores and loadings for hs-CRP, IL-6, TNF-392 
α and CXCL8 in the first principal component (PC1) and second principal component (PC2). 393 
Percentages in parenthesis are the part of the total variation in the data set explained by the 394 
components. 395 
 396 
397 
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